INTRODUCTION {#s1}
============

BRAF is a serine/threonine protein kinase of the RAF family and belongs to the RAS-RAF-MEK-ERK signalling pathway, which leads to the activation of several cytoplasmic and nuclear targets with transcriptional function, e.g. ETS11, c-JUN and c-MYC. This signalling pathway is triggered by several receptor tyrosine kinases (TKs) such as KIT and PDGFRA. In human cancer the RAS-RAF-MEK-ERK effector pathway is commonly activated, often with gain-of-function mutations in either RAS or RAF gene family members \[[@R1]\].

*BRAF* mutations have been found in a wide range of tumors (almost 7% of all cancers), both benign (melanocytic nevi \[[@R2]\], intestinal hyperplastic polyps, sessile serrated polyps/adenomas \[[@R3]\], gangliogliomas and pilocytic astrocytomas \[[@R4]\]), and malignant (hairy cell leukemia \[[@R5]\], melanomas \[[@R6]\], pleomorphic xanthoastrocytomas \[[@R4]\], papillary thyroid carcinomas \[[@R7]\], serous ovarian tumors \[[@R8]\], biliary tract carcinomas \[[@R9]\], colon adenocarcinomas \[[@R10], [@R11]\], lung adenocarcinomas \[[@R12]\], seminomas \[[@R13]\], mastocytosis \[[@R14]\] and gastroenteropancreatic neuroendocrine tumors \[[@R15]\]).

The *BRAF* mutation has also been reported in a small subset of Gastrointestinal Stromal Tumors (GIST) \[[@R16]\].

GIST are the most common mesenchymal tumor of the gastrointestinal tract \[[@R16]\]. Around 85% of sporadic primary GIST harbor activating mutations in either the *KIT* (65%) or *PDGFRA* gene (20%) \[[@R17]\], both encoding type III RTKs, and are variably sensitive to RTK-inhibitors, mainly Imatinib. The remaining cases (about 15%) represent a heterogeneous group of tumors that generally do not respond to Imatinib and include pediatric GIST, SDH-deficient GIST, NF1-associated GIST, and GIST driven by mutations downstream the TK pathway, e.g. BRAF \[[@R16]\]. The *BRAF* mutation is a rare event in primary GIST. About 8% of the cases devoid of *KIT/PDGFRA* mutations bear the *BRAF* mutation \[[@R17]--[@R21]\]. Although the use of next generation sequencing (NGS) mutation panels is gaining ground in the clinical diagnostic setting, in the majority of pathology laboratories molecular diagnosis still relies on Sanger sequencing and in most centers the *BRAF* mutation is investigated after ruling out the most common *KIT* and *PDGFRA* mutations. Hence, the frequency of this "alternative mechanism" and its co-existence with *KIT/PDGFRA* mutations is likely underestimated. *BRAF*-mutated tumors are morphologically and phenotypically indistinguishable from "classical" GIST. However, location-wise, they seem to cluster in the small bowel \[[@R17]--[@R21]\]. About 50% of the BRAF-mutated GIST reported so far fall in the AFIP high-risk category \[[@R17]--[@R21]\]. Nevertheless, their rarity and the lack of follow-up data in most series leaves uncertainty as to the correlation between pathologic risk assessment and actual clinical behavior (See Table [1](#T1){ref-type="table"}).

###### BRAF-mutated GIST in the literature

  N°       Ref.              Age/Sex   Primary/ Relapsed                               Site       Size (cm)   Morph.         Mit./ 50HPF                            AFIP Risk
  -------- ----------------- --------- ----------------------------------------------- ---------- ----------- -------------- -------------------------------------- -----------
  **1**    Agaram            52/F      Primary                                         Sm. Int.   10          Mixed          90                                     HR
  **2**    Agaram            55/F      Primary                                         Sm. Int.   10          Spindle        5                                      LR
  **3**    Agaram            49/F      Primary                                         Sm. Int.   9           Mixed          50                                     HR
  **4**    Agaram            66/M      Relapsed[\*\*](#tfn_002){ref-type="table-fn"}   Perit.     NA          Rhabdo         NA                                     NA
  **5**    Agaimy            70/M      Primary                                         Stom.      0.4         Spindle        \<5                                    NR
  **6**    Agaimy            80/M      Primary                                         Sm. Int.   0.4         Spindle        \<5                                    NR
  **7**    Hostein           53/M      Primary                                         Sm. Int.   20          Spindle        6                                      HR
  **8**    Hostein           38/M      Primary                                         Sm. Int.   2.5         Mixed          5                                      IR
  **9**    Hostein           63/M      Primary                                         Stom.      2.5         Spindle        NA                                     NA
  **10**   Hostein           78/M      Primary                                         Stom.      NA          Spindle        1                                      LR
  **11**   Hostein           51/F      Primary                                         Sm. Int.   3           Spindle        10                                     HR
  **12**   Hostein           58/M      Primary                                         Duod.      2.5         Mixed          1                                      IR
  **13**   Hostein           58/M      Primary                                         Sm. Int.   2.5         Spindle        6                                      IR
  **14**   Hostein           41/M      Primary                                         Sm. Int.   2.5         Spindle        3                                      LR
  **15**   Hostein           50/F      Primary                                         Perit.     2.8         Epith.         50                                     HR
  **16**   Miranda           NA        Primary                                         Sm. Int.   NA          NA             NA                                     HR
  **17**   Miranda           NA        Primary                                         NA         NA          NA             NA                                     NA
  **18**   Falchook          60 M      Primary                                         NA         15          Spindle        6[\*](#tfn_001){ref-type="table-fn"}   NA
  **19**   Zheng             75 M      Relapsed[\*\*](#tfn_002){ref-type="table-fn"}   Perit.     NA          Rhabdo         8                                      NA
  **20**   Rossi             69/M      Primary                                         Sm. Int.   4.6         Spindle        4                                      LR
  **21**   Rossi             36/F      Primary                                         Sm. Int.   8.5         Mixed          3                                      UR
  **22**   Rossi             66/F      Primary                                         Sm. Int.   5.4         Mixed Polym.   8                                      HR
  **23**   Rossi             63/M      Primary                                         Sm. Int.   11.2        Mixed          12                                     HR
  **24**   Rossi             42/F      Primary                                         Sm. Int.   3.8         Spindle        7                                      HR
  **25**   Rossi (current)   89/F      Primary                                         Sm. Int.   1.8         Spindle        1                                      NR

Sm. Int.= Small Intestine; Stom.= Stomach; Duod.= Duodenum; Perit.= Peritoneum; Rhabdo= Rhabdomyoblastic differentiation; Polym.= Polymorphic; HR= High Risk; IR= Intermediate Risk; LR= Low Risk; NR= No Risk; UR= Unknown Risk;

In this case the number of mitoses was counted on 10 HPF;

Tumor developed under imatinib therapy;

While the prognostic role of BRAF is still being debated, its predictive value in response to therapy is well documented. BRAF encodes a kinase molecule downstream of the TK pathways and its mutation constitutively activates the cascade, thereby bypassing the inhibitory effects of Imatinib. The *BRAF* mutation causes both *ab initio* resistance to imatinib treatment \[[@R19], [@R22]\] and secondary resistance when it occurs as a secondary event in *KIT/PDGFRA*-mutated GIST relapsing under therapy \[[@R19], [@R23]\]. Recently, a case of GIST with dual *BRAF* and *KIT* mutations has been reported in an untreated patient \[[@R21]\], challenging the concept of *KIT/PDGFRA* and *BRAF* mutation being mutually exclusive in primary GIST. These authors suggested that the concomitance of *KIT* and *BRAF* mutations might explain the resistance phenomena observed in a fraction of GIST carrying Imatinib-sensitive mutations (about 5%).

These combined data prompted us to perform a comprehensive evaluation of the involvement of BRAF kinase in GIST development and progression. To this end, we screened a series of 407 GIST cases referred to Treviso General Hospital. In addition, we sought to address the accuracy of immunohistochemistry-based screening to detect *BRAF* mutation as a surrogate for molecular analysis using BRAF V600E mutation-specific antibody VE1. This reagent has shown good sensitivity and specificity in detecting V600E-mutated cells in most, although not all, of the investigated tumor types \[[@R6], [@R24]--[@R49]\] \[[@R50]\] (See [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

RESULTS {#s2}
=======

Results from *KIT/PDGFRA/BRAF* molecular analysis are summarized in Table [2](#T2){ref-type="table"}. Only one out of the 407 cases proved to carry a *BRAF* mutation. This case, a small intestinal untreated GIST, was devoid of *KIT* or *PDGFRA* mutations. No case of concomitant *KIT* and *BRAF* or *PDGFRA* and *BRAF* mutations was found, not even in relapsed cases. Conversely, six concomitant *KIT/KIT* and one concomitant *KIT/PDGFRA* mutations were detected in seven metastases that developed under Imatinib treatment (six peritoneal and one hepatic) (Table [3](#T3){ref-type="table"}). This supports the notion that BRAF activation compensates for lack of TK mutation in GIST but does not seem to play a relevant role in secondary resistance, where *KIT* exon 13 and exon 17 mutations seem to be prevalent, in line with published data \[[@R16]\]. In addition, a double mutation was found in a localized untreated rectal GIST; in this case, both mutations involved *KIT* exon 11 (Lys558Gln and Val560del).

###### Frequency of *KIT/PDGFRA/BRAF* mutations in 407 GIST cases

  Gene                 Exon    Cases (N)                              Cases (%)
  -------------------- ------- -------------------------------------- -----------
  KIT                  11      243                                    59.7
  KIT                  9       39                                     9.6
  KIT                  13      11                                     2.7
  KIT                  17      3                                      0.8
  PDGFRA               18      37                                     9.1
  PDGFRA               12      6                                      1.5
  PDGFRA               14      4                                      1
  BRAF                 15      1                                      0.2
  KIT/PDGFRA/BRAF WT   \-      55                                     13.5
  KIT/KIT              11/11   1                                      0.2
  KIT/KIT              11/13   2[\*](#tfn_003){ref-type="table-fn"}   0.5
  KIT/KIT              11/17   3[\*](#tfn_003){ref-type="table-fn"}   0.8
  KIT/KIT              13/17   1[\*](#tfn_003){ref-type="table-fn"}   0.2
  KIT/PDGFRA           13/18   1[\*](#tfn_003){ref-type="table-fn"}   0.2
  Total                \-      407                                    100.0

Imatinib-treated GIST with double mutations

###### Cases with secondary mutations developed under Imatinib therapy

      Primary tumor   Metastasis                                                           
  --- --------------- ------------ ------------------------ ------------------ ----------- ------------------------
  1   NA              KIT/11       Met552_Pro573delinsIle   abdominal cavity   KIT/17      Tyr823Asp
  2   stomach         KIT/11       Trp557_Glu561del         abdominal cavity   KIT/13      Val654Ala
  3   NA              KIT/11       Asn566_Pro573del         abdominal cavity   KIT/17      Asn822Lys
  4   duodenum        KIT/11       Val560_Leu576del         Liver              KIT/13      Met651Ile
  5   NA              KIT/11       Glu556_Val560delinsHis   abdominal cavity   KIT/17      Asn822Lys
  6   stomach         KIT/13       Lys642Glu                abdominal cavity   KIT/17      Asn822Lys
  7   stomach         KIT/13       Lys642Glu                abdominal cavity   PDGFRA/18   Arg841_Asp842delinsLys

As for the immunohistochemical results, VE1 antibody yielded weak, non-specific, diffuse cytoplasmic staining in the normal gastric/intestinal epithelium and muscularis propria. No nuclear reactivity was observed. A clear-cut positive pattern, with fine granular cytoplasmic accumulation was evident in all four *BRAF*-mutated control GIST and the single V600E-mutated case included in our series. This reactivity was weak in two cases, moderate in one and strong in two cases (Figure [1A-1E](#F1){ref-type="fig"}), with a prevalent homogeneous pattern, but for one case where it was patchy. No reactivity was observed in *BRAF* wild-type cases. Overall, there was complete agreement in this study series (21 cases) between BRAF V600E molecular analysis and IHC, with a sensitivity and specificity of 100% (Table [4](#T4){ref-type="table"}).

###### VE1 sensitivity and specificity in the first and second study set

  --------------------------------------------------------------------
                                         Whole section set   TMA set
  -------------------------------------- ------------------- ---------
  **Cases**                              25                  288

  **BRAF-mutated cases**                 5                   1

  **BRAF-mutated VE1-positive cases**\   5\                  1\
  **(% sensitivity)**                    (100)               (100)

  **BRAF-WT VE1-positive cases**\        0\                  14\
  **(% specificity)**                    (100)               (95.1)
  --------------------------------------------------------------------

Sensitivity = 100.00 % (95% CI: 16.55 % to 100.00 %)

Specificity = 95.12 % (95% CI: 91.95 % to 97.31 %)

To corroborate this initial finding, a second set of 288 GIST, belonging to a population-based study and arranged in tissue arrays, was also analysed. The single *BRAF*-mutant case included in this series turned out to be positive for VE1, with moderate granular staining of the cytoplasm (Fig. [1](#F1){ref-type="fig"} F). Two hundred and seventy-three cases were clearly negative. Conversely, weak cytoplasmic-positive staining was observed in 14 cases, three of which belonged to the *KIT/PDGFRA/BRAF* wild-type subgroup, seven to the *KIT*-mutated and four to the *PDGFRA*-mutated subgroup. Negativity for *BRAF* mutation was double checked in these cases. In this second study set, the concordance rate between BRAF V600E molecular analysis and IHC was thus 95.1%, with a sensitivity of 100% and specificity of 95.1% (Table [4](#T4){ref-type="table"}). Importantly, none of the *BRAF*-wild-type GIST showed moderate/strong staining.

![All six BRAF V600E-mutated GIST of the series were VE1 positive, with weak cytoplasmic staining in two cases (A,B), moderate staining in two cases (C, F) and strong staining in two cases (D, E)](oncotarget-07-30109-g001){#F1}

DISCUSSION {#s3}
==========

*BRAF* mutation has been reported in a small subset of primary *KIT* and *PDGFRA* wild-type GIST \[[@R17]--[@R21]\] and in rare relapsed cases receiving Imatinib therapy \[[@R19], [@R23]\]. To date, 22 BRAF-mutated cases have been described, but the actual role of V600E mutation in GIST pathobiology is far from being defined. Except for a few studies \[[@R17], [@R18], [@R20], [@R21]\], *BRAF* status is usually investigated in *KIT/PDGFRA* mutation-negative cases only.

To investigate the relevance of concomitant *BRAF* and *KIT/PDGFRA* mutations in primary and secondary resistance to Imatinib, we conducted a molecular study of the hot spots of *KIT, PDGFRA* and *BRAF*. Only one case out of the 407 analyzed GIST carried the BRAF V600E mutation. This case was wild-type for *KIT/PDGFRA*. No concomitant mutations were found in *KIT* and *BRAF* or *PDGFRA* and *BRAF*. We detected only one double mutation in a localized/untreated context, consisting of a point mutation and a deletion affecting nearby nucleotides in *KIT* exon 11, similarly to our previous report \[[@R51]\]. Secondary mutations in *KIT*-mutated cases involved the more classical tyrosine kinase domains of KIT (exon 13 and 17) in six out of seven cases. Intriguingly, we also found one gastric GIST with a primary *KIT* exon 13 mutation (Lys642Glu) which relapsed three years later under Imatinib, with a secondary mutation in *PDGFRA* exon 18 (Arg841_Asp842delinsLys). To the best of our knowledge, this is the second case reported so far of acquired resistance involving a different kinase from the one affected by the primary mutation \[[@R52]\]. Our results support the notion that the *BRAF* mutation plays a minor role as a concomitant alteration in both primary and secondary resistance.

In order to optimize the method for detecting *BRAF*-mutated cases in GIST, we evaluated the expression of the mutation-specific antibody VE1 in a large series of GIST and compared the results with direct sequencing of *BRAF* exon 15. Our findings indicate that VE1 antibody is highly sensitive for the presence of *BRAF* V600E mutation in GIST, as all six BRAF-mutated cases scored VE1 positive with moderate/strong staining intensity in four cases. Moderate/strong staining was detected exclusively in *BRAF*-mutated GIST, whereas none of the *BRAF*-mutation negative cases displayed such intensity. These findings indicate that significantly intense VE1 staining reliably predicts the presence of *BRAF* mutation. This is in line with a recent study on a series of 38 GIST, in which VE1 strong expression was limited to the 2 *BRAF*-mutant cases included \[[@R53]\]. Additionally, in that series, a weak VE1 staining was found only in a fraction of the *BRAF*-mutation negative cases \[[@R53]\]. Differently, in our series, 2 out of 6 *BRAF*-mutant cases showed only a weak VE1 staining, as well as 14 out of 287 (4.9%) *BRAF* wild-type cases. Hence, our results should caution the pathologist to interpret as either negative or positive for *BRAF*-mutation those GIST that show a weak VE1 expression. Instead, we consider that in presence of a weak staining, the molecular assessment of *BRAF* gene status is highly recommended.

Although the frequency of the *BRAF* mutation in GIST is limited (\<1%), the presence of this mutation has a high impact on patients\' management. If on one hand it causes resistance to TK-inhibitors \[[@R18], [@R22]\], on the other it sensitizes the tumor to BRAF inhibitors. Falchook *et al*. recently reported a GIST case effectively treated with Dabrafenib \[[@R22]\]. NGS is gaining ground in the diagnostic setting, thus allowing for the simultaneous assessment of a wider set of molecular biomarkers. While waiting for this approach to be fully implemented by pathology laboratories, we believe that at the present time VE1 immunostaining may represent a valuable tool to address BRAF mutation status in GIST.

MATERIALS AND METHODS {#s4}
=====================

Tumor samples {#s4_1}
-------------

To investigate the role of *BRAF* mutation in GIST, *KIT* (exon 9, 11, 13, 17), *PDGFRA* (exon 12, 14, 18) and *BRAF* (exon 15) mutations were sequenced in a series of 407 cases (including 358 personal consultation cases referred to one of the authors \[ADT\], and 49 in-house cases) from 398 patients. Eight patients had multiple GIST either in the context of neurofibromatosis (three cases) or in a non-syndromic context (five cases) \[[@R54]\]. Informed consent was obtained from all living patients. Two hundred and fifteen were men and 183 were women. Age ranged between 24 and 91 years (median 63). Clinical records were available for 344 of the 398 patients. Two hundred and eighty-seven out of 353 tumors were primary GIST: 262 located in the gastrointestinal tract (142 gastric, 17 duodenal, 88 from the small intestine, one from the colon, 14 from the sigma-rectum) and 23 extra-gastrointestinal (12 from the abdominal cavity and pelvis, and nine from the retro-peritoneum). The remaining 68 cases were either relapsed or metastatic GIST.

The median size of the primary tumors was 5.5 cm (range 0.5 to 35 cm) and the median mitotic index was 4/50 HPF (range 0 to 180). The risk category could be determined in 221 cases on the basis of the AFIP classification (17 no risk, 13 very low, 61 low, 49 intermediate and 81 high risk tumors).

The predictive value of VE1 staining, as a surrogate for BRAF mutation analysis, could be assessed by immunohistochemistry on a subset of 21 (in-house) cases. Four GIST carrying the BRAF V600E mutation were retrieved from a previous series \[[@R17]\] and included as positive controls.

A further series of 288 cases, arranged in 25 tissue microarrays (TMA) deriving from a large population-based Italian study \[[@R17]\] \[[@R55]\], was also tested for VE1. Each tumour was represented by two to four cores in each array. In this study set, *KIT/PDGFRA/BRAF* status had previously been determined by sequential screening of the different exons until the mutation was detected, in the following order: *KIT* exon 11, *KIT* exon 9, *PDGFRA* exon 18, *PDGFRA* exons 12 and 14, *KIT* exons 13 and 17. Cases devoid of *KIT/PDGFRA* mutation were further investigated for BRAF V600 mutations \[[@R17]\]. Of these 288 cases, one was B*RAF*-mutated (V600E), 188 were *KIT*-mutated (165 with exon 11, 18 with exon 9, three with exon 13 and two with exon 17 mutation), 61 were *PDGFRA*-mutated (49 with exon 18, five with exon 14, six with exon 12 mutation), one case carried a double *KIT* mutation (Asn659Asp and Pro567Leu), and 38 were wild-type. Three of the 165 *KIT* exon 11 mutations were homozygous.

Molecular analyses {#s4_2}
------------------

DNA was extracted from representative blocks of formalin-fixed/paraffin-embedded tissues with tumor cellularity greater than 80%. 10-μm-thick sections were deparaffinized by serial xylene/ethanol washings. DNA was extracted using the EZ1 Biorobot (Qiagen GmbH). KIT, PDGFRA and BRAF mutation analysis was performed by PCR and Sanger sequencing using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), as previously described \[[@R17]\] \[[@R51]\] \[[@R54]\].

Immunohistochemistry {#s4_3}
--------------------

Immunohistochemistry (IHC) was performed on freshly-cut 3-μm-thick, paraffin-embedded tissue sections, using VE1 antibody specific for BRAF V600E mutation (clone VE1, Spring Bioscence, Pleasanton, CA). Only cases for which the block was available to provide freshly cut sections were included in the study. To optimize the method, a range of conditions were tested, in relation to both antibody dilution (1:25, 1:50, 1:100) and antigen retrieval (pH6 and pH9 buffer). A series of 10 melanomas, eight with V600E mutation and two with alternative BRAF mutations (V600K, K601E), were used as positive and negative control cases, respectively.

The selected protocol included heat-induced epitope retrieval (PTLINK Dako) with high pH (pH9) and antigen-antibody reaction at 1:100 dilution for 40 minutes (KIT ENVISION FLEX, Dako) in an automated immunostainer (Dako Autostainer, DakoCytomation, Glostrup, Denmark). For four BRAF-mutated cases, VE1 antibody was also tested on whole sections which had been cut seven years earlier. Notably, the intensity of the staining was much weaker than the results obtained on the freshly-cut sections, highlighting that the time gap between cutting and staining highly impacts on VE1 performance.

All immunostained slides were evaluated with blinding to clinical, histopathologic and genetic data by three histopathologists of varying experience. Interobserver agreement was high with approximately 10% of the cases re-reviewed collegially. Where there was any disagreement, the sections were re-reviewed and a consensus opinion reached.

Tumors were considered as positive when the tumor cells showed weak, moderate or strong cytoplasmic staining, and as negative when the tumor cells showed either faint cytoplasmic staining or no staining.

SUPPLEMENTARY MATERIAL TABLE {#s5}
============================
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